RESUMO
BACKGROUND: Several studies have indicated that intrapleural infusion of bevacizumab is an effective treatment for non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE). However, the impact of bevacizumab administered through an indwelling pleural catheter (IPC) on the prognosis of these patients is unknown. METHODS: Consecutive advanced NSCLC patients with symptomatic MPE receiving an IPC alone or bevacizumab through an IPC were identified in a tertiary hospital. The patient characteristics and clinical outcomes were collected. RESULTS: A total of 149 patients were included, and the median age was 60.3 years. Males and nonsmokers accounted for 48.3% and 65.8%, respectively. A total of 69.8% (104/149) of patients harbored actionable mutations, including 92 EGFR-activating mutations, 11 ALK fusions, and 1 ROS1 fusion. A total of 81.9% (122/149) of patients received IPC alone, and 18.1% (27/149) received bevacizumab through an IPC. The incidence of spontaneous pleurodesis during the first 6 months was greater in the bevacizumab-treated group than in the IPC-treated group in the subgroup with actionable mutations (64.3% vs. 46.9%, P = 0.28). The median overall survival (OS) in patients with actionable mutations treated with bevacizumab through an IPC was 42.2 months, which was significantly longer than the 26.7 months in patients who received an IPC alone (P = 0.045). However, the median OS did not differ between the two arms in the subgroup without actionable mutations (10.8 vs. 41.0 months, P = 0.24). No significant difference between the bevacizumab through an IPC group and the IPC group was detected in the number of participants who had adverse events, either in patients with actionable mutations (14.3% vs. 8.4%; P = 0.42) or in patients without actionable mutations (16.7% vs. 12.8%; P = 1.00). CONCLUSIONS: Bevacizumab through an IPC resulted in a significantly improved prognosis for NSCLC patients with MPE and actionable mutations. However, patients without actionable mutations do not benefit from bevacizumab through IPC.
Assuntos
Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Derrame Pleural Maligno , Masculino , Humanos , Pessoa de Meia-Idade , Carcinoma Pulmonar de Células não Pequenas/complicações , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/genética , Bevacizumab/uso terapêutico , Derrame Pleural Maligno/etiologia , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/genética , Proteínas Tirosina Quinases , Proteínas Proto-Oncogênicas , Cateteres de Demora/efeitos adversosRESUMO
Malignant pleural effusion (MPE) can occur in nearly all types of malignant tumors, with lung cancer being the most prevalent cause. The presence of MPE indicates an advanced stage or distant spread of the tumor, significantly reducing the patient's life expectancy. Particularly, a substantial amount of pleural effusion can impede heart and lung function, impair blood oxygen perfusion levels in the body, and greatly diminish patients' quality of life. Even when systemic treatment has alleviated the primary lung tumor in some patients, effective control over MPE remains challenging and impacts clinical outcomes. Therefore, it is crucial to implement measures for reducing or managing MPE while ensuring standardized treatment for lung cancer. In recent years, significant advancements have been made in diagnosing and treating lung cancer complicated by MPE through extensive basic and clinical research. Based on existing evidence and China's clinical practice experience, relevant experts from the China Association of Health Promotion and Education and Cancer Rehabilitation and Palliative Treatment Professional Committee of China Anti-Cancer Association (CRPC) have summarized key aspects related to diagnosis and treatment consensus opinions for lung cancer complicated by MPE. This aims to establish standardized procedures that will serve as a reference for doctors' clinical practice.
Assuntos
Neoplasias Pulmonares , Derrame Pleural Maligno , Derrame Pleural , Humanos , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/diagnóstico , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/terapia , Consenso , Qualidade de Vida , Derrame Pleural/diagnóstico , Derrame Pleural/etiologia , Derrame Pleural/terapiaRESUMO
Malignant pleural effusion is a common diagnosis in metastasized cancers. It is always of palliative character. Main symptoms are dyspnoea and reduced quality of life. Diagnosis is made by ultrasound-guided puncture of the pleural effusion (cytology) and often video-assisted thoracic surgery with biopsy of the pleural surface (histology). The goal of treatment is a fast, sustainable, minimally invasive, patient-centred therapy that increases quality of life. Besides systemic therapy and best supportive care the patient can be treated with local therapy including either pleurodesis (via drainage or VATS) or an indwelling-pleural catheter (IPC). Decision for one of these procedures is made upon performance index (ECOG), expandability of the lung, prognosis and the patient's wish. For the first technique, the lung must be expandable. The latter one (IPC) can be implanted both with expandable and trapped lung. Both are similarly effective in symptom control.
Assuntos
Cuidados Paliativos , Derrame Pleural Maligno , Pleurodese , Cirurgia Torácica Vídeoassistida , Derrame Pleural Maligno/terapia , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/diagnóstico , Humanos , Drenagem , Cateteres de Demora , Qualidade de Vida , Prognóstico , Ultrassonografia de IntervençãoRESUMO
Malignant effusion complicates more than 15% of all cancers in delayed stages of progression. The most common causes of metastatic pleuritis are lung cancer, breast cancer, ovarian cancer, lymphoproliferative diseases or dissemination of gastrointestinal tumors. Malignant effusion is associated with negative prognosis for overall survival regardless of etiology of tumor, significantly complicates the course of the underlying disease, impairs life quality and complicates treatment. Despite various methods for pleural cavity obliteration in recurrent metastatic pleuritis, there is still no a uniform approach to choosing the optimal treatment strategy. We analyzed the main methods of conservative and surgical treatment of recurrent metastatic pleuritic regarding efficacy, risk of recurrence and reproducibility.
Assuntos
Derrame Pleural Maligno , Humanos , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/terapia , Derrame Pleural Maligno/diagnóstico , Prognóstico , Pleurisia/etiologia , Pleurisia/diagnóstico , Qualidade de VidaRESUMO
Exudative pleural effusion appears as manifestation of underlying specific disease process and pleural biopsy is usually enough to find out the underlying causative disease. The aim of the study was to find out the efficacy of needle biopsy of pleura in the aetiological diagnosis of pleural effusion. This cross-sectional study was conducted for a period of one year from January 2008 to December 2008 in the Department of Medicine, Shaheed Ziaur Rahman Medical College Hospital, Bogura, Bangladesh enrolling 50 subjects with exudative pleural effusion. The cases with transudative pleural effusion were not included. Needle biopsy was done in all the cases. Histopathological reports of pleural biopsy specimen were correlated with other data and analyzed to detect the causes of effusion. Major incidence of malignant effusion occurred between 41 to 70 years of age. No malignant effusion was found before 30 years of age. Incidence of tuberculous and malignant pleural effusion was much more common in males than in females. Sensitivity and specificity of combined pleural biopsy and pleural fluid analysis in the diagnosis of pleural effusion was 97.06% and 100.% for tuberculosis and 81.82% and 100.0% for malignancy. The present study reveals that pleural biopsy was very effective method in the diagnosis of cause of pleural effusion.
Assuntos
Derrame Pleural , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Derrame Pleural/etiologia , Derrame Pleural/patologia , Derrame Pleural/diagnóstico , Adulto , Estudos Transversais , Biópsia por Agulha/métodos , Pleura/patologia , Derrame Pleural Maligno/patologia , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/etiologia , Sensibilidade e Especificidade , AdolescenteRESUMO
BACKGROUND Fluid overload-associated large B-cell lymphoma (FO-LBCL) is a recently described malignant lymphoma that presents with serous effusions in the pleura, peritoneum, and/or pericardium but without an identifiable lymphoma mass. This report describes the case of an 80-year-old man who presented with a pleural effusion and describes the approach to diagnosis and management of FO-LBCL. CASE REPORT We present a case of an 80-year-old man who presented with right pleural effusion and shortness of breath at work. Initial radiological assessment suggested a pleural effusion on the right side, without an identifiable mass, given the patient's symptoms and imaging characteristics. Subsequently, he underwent a pleural fluid puncture and biopsy. Based on the initial pathological assessment, malignant lymphoma, a non-epithelial tumor, was considered likely, but differentiation from reactive proliferative cells was difficult, given the patient's symptoms and cytologic characteristics. Postoperatively, histopathological examination and immunohistochemistry confirmed a diagnosis of FO-LBCL. After 1 year of follow-up, the condition had progressed and the patient died due to recurrence. CONCLUSIONS This report has presented a case of FO-LBCL in an elderly man with pleural effusion and described how this rare and recently described lymphoma was diagnosed and managed.
Assuntos
Linfoma Difuso de Grandes Células B , Humanos , Masculino , Idoso de 80 Anos ou mais , Linfoma Difuso de Grandes Células B/patologia , Linfoma Difuso de Grandes Células B/complicações , Linfoma Difuso de Grandes Células B/diagnóstico , Plasmócitos/patologia , Derrame Pleural Maligno/etiologia , Evolução Fatal , Derrame Pleural/etiologiaRESUMO
Multiple myeloma is a malignant plasma cell condition that mostly affects the skeletal system and bone marrow. Pleural effusions are uncommon and typically result from other conditions coexisting with multiple myeloma. Malignant myelomatous pleural effusions are rare complications of multiple myeloma, occurring in less than 1% of patients and are associated with poor prognosis having mean survival of less than 4 months. The present case report is a 41-year-old multiple myeloma patient who developed bilateral pleural effusion at a disease relapse. Chemotherapeutic regimen of cyclophosphamide, bortezomib, and dexamethasone given. Despite a positive response to treatment, the patient's condition worsened over the course of following month and he eventually passed away. Myelomatous pleural effusion indicates poor prognosis and early consideration helps in quick diagnosis and initiation of treatment which may help in improving prognosis.
Assuntos
Mieloma Múltiplo , Derrame Pleural Maligno , Derrame Pleural , Masculino , Humanos , Adulto , Mieloma Múltiplo/complicações , Mieloma Múltiplo/diagnóstico , Mieloma Múltiplo/tratamento farmacológico , Recidiva Local de Neoplasia/patologia , Derrame Pleural/diagnóstico , Derrame Pleural/etiologia , Derrame Pleural/patologia , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/tratamento farmacológico , Derrame Pleural Maligno/etiologia , Plasmócitos/patologiaRESUMO
Multiple myeloma is a rare haematological malignancy characterised by the clonal proliferation of plasma cells within the bone marrow. Typical manifestations include bone pain, fatigue and monoclonal protein elevation in serum and urine. Less than 1% of cases develop myelomatous pleural effusion, a severe complication indicative of advanced disease and a very poor prognosis.Here, we present a case of a woman with a new diagnosis of multiple myeloma complicated by bilateral myelomatous pleural effusions as the initial presentation. This case underscores the diverse clinical spectrum of multiple myeloma, the significance of timely diagnosis and the threatening implications associated with myelomatous pleural effusions.
Assuntos
Mieloma Múltiplo , Derrame Pleural Maligno , Humanos , Mieloma Múltiplo/complicações , Mieloma Múltiplo/diagnóstico , Feminino , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/diagnóstico por imagem , Pessoa de Meia-Idade , Idoso , Derrame Pleural/etiologia , Derrame Pleural/diagnósticoRESUMO
BACKGROUND/AIMS: Epidermal growth factor receptor (EGFR) mutation is important in determining the treatment strategy for advanced lung cancer patients with malignant pleural effusion (MPE). Contrary to serum carcinoembryonic antigen (S-CEA) levels, the associations between pleural fluid CEA (PF-CEA) levels and EGFR mutation status as well as between PF-CEA levels and treatment efficacy have rarely been investigated in lung adenocarcinoma patients with MPE. METHODS: This retrospective study enrolled lung adenocarcinoma patients with MPE and available PF-CEA levels and EGFR mutation results. The patients were categorized based on PF-CEA levels: < 10 ng/mL, 10-100 ng/mL, 100-500 ng/mL, and ≥ 500 ng/mL. The association between PF-CEA levels and EGFR mutation status as well as their therapeutic impact on overall survival was compared among the four groups. RESULTS: This study included 188 patients. PF-CEA level was found to be an independent predictor of EGFR mutation but not S-CEA level. The EGFR mutation rates were higher as the PF-CEA levels increased, regardless of cytology results or sample types. Among EGFR-mutant lung adenocarcinoma patients receiving EGFR-tyrosine kinase inhibitor (TKI) treatment, those with high PF-CEA levels had significantly better survival outcomes than those with low PF-CEA levels. CONCLUSION: High PF-CEA levels were associated with high EGFR mutation rate and may lead to a favorable clinical outcome of EGFR-TKI treatment in EGFR-mutant lung adenocarcinoma patients with MPE. These findings highlight the importance of actively investigating EGFR mutation detection in patients with suspected MPE and elevated PF-CEA levels despite negative cytology results.
Assuntos
Adenocarcinoma de Pulmão , Neoplasias Pulmonares , Derrame Pleural Maligno , Derrame Pleural , Humanos , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/terapia , Antígeno Carcinoembrionário/genética , Antígeno Carcinoembrionário/uso terapêutico , Estudos Retrospectivos , Inibidores de Proteínas Quinases/uso terapêutico , Adenocarcinoma de Pulmão/genética , Adenocarcinoma de Pulmão/tratamento farmacológico , Adenocarcinoma de Pulmão/patologia , Neoplasias Pulmonares/tratamento farmacológico , Receptores ErbB/genética , Derrame Pleural/induzido quimicamente , Derrame Pleural/diagnóstico , Derrame Pleural/tratamento farmacológico , MutaçãoRESUMO
INTRODUCTION AND IMPORTANCE: Lung adenocarcinoma may resemble the clinical presentation of an infectious or inflammatory lung disease. The coexistence of lung cancer, and polyserous effusions is uncommon, which may cause a diagnostic challenge. However, any polyserous effusions at a young age must always be suspicious for malignancy. CASE PRESENTATION: We report a case of 38-year-old male patient with polyserous effusions and pneumonia who was treated accordingly and showed clinical improvement with a significant reduction of pericardial and pleural effusions. Subsequent testing and a biopsy resulted in the histopathological diagnosis of an adenocarcinoma of the lung. CLINICAL DISCUSSION: Nonrecurrent polyserous effusions in lung adenocarcinoma are uncommon, and negative cytology results may not exclude malignancy due to the moderate sensitivity of pleural and pericardial fluid cytology. Clinicians should remain vigilant for false-negative results, especially in younger patients. Malignancy should not be ruled out because pleural and pericardial fluid cytology have a sensitivity of 60% and 92%, respectively. CONCLUSION: Our case highlights the diagnostic challenges posed by atypical presentations of lung adenocarcinoma and emphasizes the importance of considering malignancy in the differential diagnosis of polyserous effusions, even when initial cytology results are negative. Clarifying the rationale for this study enhances its relevance and impact.
Assuntos
Adenocarcinoma de Pulmão , Neoplasias Pulmonares , Pneumonia , Humanos , Masculino , Adulto , Diagnóstico Diferencial , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/complicações , Adenocarcinoma de Pulmão/diagnóstico , Adenocarcinoma de Pulmão/patologia , Pneumonia/diagnóstico , Derrame Pericárdico/etiologia , Derrame Pericárdico/diagnóstico , Derrame Pericárdico/patologia , Derrame Pleural/diagnóstico , Derrame Pleural/etiologia , Adenocarcinoma/diagnóstico , Adenocarcinoma/patologia , Derrame Pleural Maligno/patologia , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/etiologia , CitologiaRESUMO
BACKGROUND: The distinction between lung adenocarcinoma-associated malignant pleural effusion (MPE) and tuberculous pleural effusion (TPE) continues to pose a challenge. This study sought to assess the supplementary value of tumor markers in enabling a differential diagnosis. METHODS: Data concerning tumor markers, which included carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cancer antigen 153 (CA153), cancer antigen 724 (CA724), neuron-specific enolase (NSE), cytokeratin19 fragment (Cyfra21-1), and squamous cell carcinoma antigen (SCCA), in both serum and pleural effusion samples, were retrospectively compiled from lung adenocarcinoma-associated MPE and TPE patients. A comparative analysis of tumor marker concentrations between the two groups was performed to assess diagnostic utility, followed by a multiple logistic regression to control for confounding variables. RESULTS: While gender, serum CA125 and SCCA, and pleural effusion SCCA manifested comparability between the groups, distinctions were noted in patient age and the concentration of other tumor markers in serum and pleural effusion, which were notably elevated in the MPE group. Multiple logistic regression demonstrated a positive association between the risk of lung adenocarcinoma-associated MPE and levels of CEA and CA153 in serum and pleural effusion, as well as Cyfra21-1 in serum (P < 0.05). The odds ratio for CEA surpassed that of CA153 and Cyfra21-1. CONCLUSIONS: CEA and CA153 in serum and pleural effusion, and Cyfra21-1 in serum emerge as biomarkers possessing supplementary diagnostic value in distinguishing lung adenocarcinoma-associated MPE from TPE. The diagnostic efficacy of CEA is superior to CA153 and Cyfra21-1. Conversely, the utility of CA125, CA724, NSE, and SCCA appears constrained.
Assuntos
Antígenos de Neoplasias , Biomarcadores Tumorais , Antígeno Ca-125 , Antígeno Carcinoembrionário , Queratina-19 , Neoplasias Pulmonares , Derrame Pleural Maligno , Derrame Pleural , Humanos , Masculino , Biomarcadores Tumorais/sangue , Feminino , Pessoa de Meia-Idade , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/complicações , Neoplasias Pulmonares/sangue , Idoso , Diagnóstico Diferencial , Derrame Pleural Maligno/diagnóstico , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/metabolismo , Derrame Pleural Maligno/sangue , Antígenos de Neoplasias/sangue , Antígeno Ca-125/sangue , Estudos Retrospectivos , Derrame Pleural/diagnóstico , Derrame Pleural/etiologia , Queratina-19/sangue , Antígeno Carcinoembrionário/sangue , Antígeno Carcinoembrionário/análise , Adenocarcinoma de Pulmão/diagnóstico , Adenocarcinoma de Pulmão/complicações , Tuberculose Pleural/diagnóstico , Tuberculose Pleural/complicações , Antígenos Glicosídicos Associados a Tumores/sangue , Antígenos Glicosídicos Associados a Tumores/análise , Fosfopiruvato Hidratase/sangue , Fosfopiruvato Hidratase/análise , Adenocarcinoma/diagnóstico , Adenocarcinoma/complicações , Adulto , Serpinas/sangue , Idoso de 80 Anos ou maisRESUMO
Multiple myeloma is a common malignant bone-based disease. Pleural effusions reported in these patients remain rare. It is commonly due to congestive heart disease, pulmonary embolism, nephrotic syndrome or a second neoplasia. The true myelomatous pleural effusion resulting from a direct tumoral invasion of the pleural are extremely rare. We report here the case of a massive pleural effusion revealing multiple myeloma in a 71-year-old patient. The chest ultrasound showed a massive pleural effusion in the left side with a multinodular thickening of the pleura. The medical thoracoscopy showed a grape-cluster appearance. The diagnosis was made by pleural guided biopsy revealing abnormal plasma cells with an intense positive CD 138 (plasma cell marker) and MUM1 (multiple myeloma oncogene1) staining with a light kappa chain in the protein electrophoresis associated with a myeloma. Unfortunately, our patient died one month after the initial diagnosis. We present also a review of the recent literature in order to highlight the clinical presentations of the myelomatous pleural effusion, the diagnostic tools, the therapeutic strategies as well as the outcomes.
Assuntos
Mieloma Múltiplo , Humanos , Mieloma Múltiplo/complicações , Mieloma Múltiplo/diagnóstico , Mieloma Múltiplo/patologia , Idoso , Masculino , Derrame Pleural/diagnóstico , Derrame Pleural/etiologia , Derrame Pleural/patologia , Derrame Pleural/diagnóstico por imagem , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/patologia , Derrame Pleural Maligno/diagnóstico , Evolução FatalRESUMO
Wilms tumor (WT) is the most common renal malignancy seen in pediatric patients. Although lungs are the most common site of metastasis in Wilms tumor, non-malignant pleural effusion has been infrequently reported. Here, we report a case of an eleven-year-old female who presented with an abdominal mass and progressive breathlessness. On further evaluation, she was found to have a right-sided Wilms tumor with ipsilateral massive pleural effusion. The effusion resolved almost completely after four weeks of chemotherapy. We conclude that patients suffering from Wilms tumor presenting with pleural effusion need not be synonymous with metastatic disease and can have a favorable prognosis.
Assuntos
Neoplasias Renais , Tumor de Wilms , Humanos , Tumor de Wilms/complicações , Tumor de Wilms/patologia , Feminino , Neoplasias Renais/complicações , Neoplasias Renais/patologia , Criança , Derrame Pleural/etiologia , Derrame Pleural/patologia , Derrame Pleural Maligno/patologia , Derrame Pleural Maligno/etiologiaAssuntos
Leucemia-Linfoma Linfoblástico de Células T Precursoras , Humanos , Leucemia-Linfoma Linfoblástico de Células T Precursoras/complicações , Derrame Pleural/etiologia , Derrame Pleural/diagnóstico por imagem , Masculino , Criança , Feminino , Derrame Pleural Maligno/etiologia , Derrame Pleural Maligno/diagnóstico por imagemRESUMO
Multiple myeloma (MM) is a malignant neoplasm of monoclonal plasma cells that accumulate in bone marrow (BM). Malignant pleural effusions (MPE), as part of multiple myeloma clinical presentation, are unusual. Is even more rare as the first sign of presentation, occurring in less than 1% of the cases. The most common associated immunoglobulin with malignant pleural effusions is IgA subtype (80%). This condition carry a poor prognosis. We aim to describe a refractory case of multiple myeloma with extensive disease that presented with extramedullary relapse with malignant pleural effusions , besides discussing the importance of differential diagnosis.
O mieloma múltiplo (MM) é uma neoplasia maligna de células plasmáticas monoclonais que se acumulam na medula óssea (MO). Os derrames pleurais malignos (EPM), como parte da apresentação clínica do mieloma múltiplo, são incomuns. É ainda mais raro como primeiro sinal de apresentação, ocorrendo em menos de 1% dos casos. A imunoglobulina associada mais comum a derrames pleurais malignos é o subtipo IgA (80%). Esta condição carrega um mau prognóstico. Nosso objetivo é descrever um caso refratário de mieloma múltiplo com doença extensa que apresentou recidiva extramedular com derrame pleural maligno, além de discutir a importância do diagnóstico diferencial
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Derrame Pleural Maligno/etiologia , Mieloma Múltiplo/complicações , Imuno-Histoquímica , Radiografia , Leucemia Plasmocitária/diagnóstico , Tomografia Computadorizada por Raios X , Derrame Pleural Maligno/patologia , Derrame Pleural Maligno/diagnóstico por imagem , Evolução FatalRESUMO
In the last years important advances have taken place in the surgical field allowing to treat practically all pleural pathologies by video-assisted thoracic surgery (VATS), with prompt recovery and minimal morbidity and mortality. Internists had also perfected the medical thoracoscopy, a technique used for the study of pleural diseases, which also allows performing some therapeutic procedures. The present article briefly comments the history of medical thoracoscopy and VATS and their current applications. A critical analysis of the principal indications of medical thoracoscopy is presented: study of pleural effusions, management of malignant pleural effusion and spontaneous pneumothorax. The results are compared, in view of the existing evidence, with other less complex surgical procedures and VATS.
En los últimos años se han producido importantes avances en las técnicas quirúrgicas que permiten tratar prácticamente todas las patologías pleurales y pulmonares por videotoracoscopía, con una rápida recuperación postoperatoria y mínima morbi-mortalidad. Se ha perfeccionado además por médicos internistas la toracoscopía médica, técnica utilizada para el estudio de las enfermedades de la pleura, que permite también realizar algunos procedimientos terapéuticos. En el presente artículo se comenta brevemente la historia de la videotoracoscopía y la toracoscopía médica y sus aplicaciones actuales. Se realiza un análisis crítico de las principales indicaciones de la toracoscopía médica: estudio de derrames pleurales, manejo del derrame pleural de origen neoplásico y del neumotorax espontáneo. Sus resultados se comparan, a la luz de la evidencia existente, con otros procedimientos quirúrgicos menos complejos y con la videotoracoscopía.
Assuntos
Humanos , Cirurgia Torácica Vídeoassistida/métodos , Derrame Pleural/cirurgia , Doenças Pleurais/cirurgia , Derrame Pleural Maligno/cirurgia , Derrame Pleural Maligno/etiologia , Doenças Pleurais/patologia , Neoplasias/patologia , Procedimentos Cirúrgicos Minimamente Invasivos/métodos , Toracoscopia/métodosRESUMO
INTRODUCCION: El objetivo del estudio fue establecer la causa de la efusión pleural de los pacientes que consultaron al Hospital Universitario Ramón González Valencia en un período de siete años y realizar comparaciones por edad y sexo. MATERIALES Y METODOS: A todos los pacientes que ingresaron al estudio se les realizó historia clínica, examen físico, citología de líquido pleural, biopsia pleural y estudios complementarios cuando fuere necesario. RESULTADOS: Se estudiaron 200 pacientes con efusión pleural, con edad promedio de 46.5 años. Las cuatro principales causas en orden de frecuencia fueron: Tuberculosis (38.5 por ciento), cardiopatías (13.5 por ciento) y enfermedad infecciosa aguda del pulmón (11 por ciento). No se encontraron diferencias según sexos pero si fue más frecuente entre los 41-60 años y menos frecuente en los extremos de la vida. CONCLUSIONES: Continúan siendo la citología de líquido pleural y la biopsia las pruebas más eficaces que el médico debe elegir para esclarecer la etiología de la efusión pleural. La tuberculosis y las neoplasias continúan siendo las principales causas de esta entidad